Table 1

Therapy of L3.6pl pancreatic tumors in nude mice with C225 and gemcitabine

TherapyaIncidence of macroscopic tumorsbTotal pancreas weight mg (range)eMedian tumor volume mm3 (range)fMedian body weight g (range)
Pancreas tumorLiver metastasiscRegional LN metastasisd
Control10 /105 /1010 /10923 (660–1371)539 (254–860)22 (16–24)
Gemcitabine10 /103 /106 /10297 (205–485)152 (59–365)22 (18–29)
C2255 /102 /108 /10119 (97–157)0.3 (0–13)25 (21–28)
C225+ gemcitabine0 /90 /91 /9130 (93–173)0 (0)23 (20–27)
  • a L3.6pl cells (1 × 106) were implanted into the pancreas. Therapy began on day 7, when median tumor size was 18 mm3. C225 (1 mg), Gemcitabine (250 mg/kg), alone or in combination, was injected i.p. biweekly for 4 weeks. Control mice received saline. Tumor weight and metastases were evaluated at necropsy at day 32. One experiment of two is shown.

  • b Number of tumor-positive mice per number of mice receiving injections.

  • c Number of mice with visible nodules (>1 mm in diameter) per number of mice receiving injections.

  • d Number of mice with enlarged regional lymph nodes (LN) per number of mice receiving injections.

  • e P < 0.0001 (unpaired Student’s t test) control versus all three therapy groups.

  • f Tumor volume was calculated by the formula: v = ab2/2, where a is the longest diameter and b is the shortest diameter of the tumor. P < 0.0001 control versus all three therapy groups and C225 versus C225 plus gemcitabine therapy group.